| Title |
Year |
Author |
Number |
| SOMATOSTATIN RECEPTOR ANTAGONISTS |
1997 |
- Morgan Behrri
- Merfi Vill'Jam
- Koj Dehvid Kh.
|
RU2179172C2 |
| METHOD OF REGULATING FOLLICULAR RESERVE OF OVARY, METHOD OF TREATING DEVIATIONS IN GROWTH OF RESTING FOLLICLES IN WOMEN, MEDICATION OF FOLLICLE DEVELOPMENT STIMULATION AND MEANS OF DETERMINING IMPACT OF COMPOUNDS ON ACCELERATION OR RETARDATION OF FOLLICLE GROWTH IN CARRYING OUT TOXICOLOGICAL TESTS (VERSIONS) |
2004 |
|
RU2418604C9 |
| NEUROMEDIN AND SOMATOSTATIN RECEPTOR AGONISTS |
2000 |
- Sadat-Aalai Din
- Morgan Barri A.
|
RU2263680C2 |
| PEPTIDE VECTORS |
2004 |
- Dong Chzhen Ksin
- Shen Jilana
- Komstok Dzhinn Mehri
- Kim San Kh.
|
RU2361876C2 |
| PHOSPHORYLATED POLYMERS AND THEIR CONJUGATES |
1999 |
- Shalabi Shalabi Vakhba
- Korbett Dzhoel Tomas
|
RU2202563C2 |
| CONJUGATES OF CYTOTOXIC AGENTS WITH PEPTIDES |
2007 |
- Dong Chzhen Ksin
- Shen Jilana
- Kaller Majkl Devitt
- Tjur'O Kristof Alen
- Chzhan Tszjun'Dun
- Kim Sun' Khjuk
|
RU2457218C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES |
2015 |
- Bourne, Gregory
- Bhandari, Ashok
- Cheng, Xiaoli
- Frederick, Brian Troy
- Zhang, Jie
- Patel, Dinesh V.
- Liu, David
|
RU2736637C2 |
| UROTENSIN-II AGONISTS AND ANTAGONISTS |
2001 |
- Koj Dehvid Kh.
- Rossovski Vojtsekh J.
|
RU2263679C2 |
| CHIMERIC EQUIVALENTS OF LIGANS OF SOMATOSTATIN AND DOPERMINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS BASED ON THEM AND MODALTIES OF SOMATOSTATIN AND/DOPERMINE RECEPTORS |
2004 |
- Dong Chzhen Ksin
- Devitt Kaller Majkl
- Shen Jilana
|
RU2329273C2 |
| CYCLOPEPTIDES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD OF ITS PREPARING |
1996 |
- Al'Fred Jonchik
- Simon Goodman
- Beate Difenbakh
- Arne Zutter
- Gjunter Khel'Tsemann
- Khorst Kessler
- Mikhel' Dekhantsrajter
|
RU2157379C2 |
, (II) 
or (III) 
(radical values see in p. 1 of the claim) showing the enhanced and prolonged biological activity as compared with that of nonmodified somatostatin. EFFECT: enhanced activity and effectiveness of the peptide derivative. 17 cl, 4 tbl, 1 dwg, 9 ex
